Norbert Schmitz
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017; 390:2790-2802.
Oct 20, 2017PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Oct 20, 2017Lancet 2017; 390:2790-2802
Borchmann Peter, Bentz Martin, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Schmitz Norbert, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Kuhnert Georg, Diehl Volker, Dietlein Markus, Hitz Felicitas, Topp Max S, Goergen Helen, Kobe Carsten, Lohri Andreas, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Hüttmann Andreas, Dierlamm Judith, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, Engert Andreas
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC
Paul U, Stein H, Hansmann M, Möller P, Szczepanowski M, Burkhardt B, Pfreundschuh M, Schmitz N, Loeffler M, Trümper L, Siebert R, Cogliatti S, Feller A, Rosenwald A, Richter J, Stuhlmann-Laiesz C, Kreuz M, Nagel I, Horn H, Staiger A, Aukema S, Hummel M, Ott G, Spang R, Klapper W. Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. Leuk Lymphoma 2017:1-9.
Aug 25, 2017Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC
Aug 25, 2017Leuk Lymphoma 2017:1-9
Paul Ulrike, Stein Harald, Hansmann Martin-Leo, Möller Peter, Szczepanowski Monika, Burkhardt Birgit, Pfreundschuh Michael, Schmitz Norbert, Loeffler Markus, Trümper Lorenz, Siebert Reiner, Cogliatti Sergio B., Feller Alfred C, Rosenwald Andreas, Richter Julia, Stuhlmann-Laiesz Christiane, Kreuz Markus, Nagel Inga, Horn Heike, Staiger Annette M, Aukema Sietse M, Hummel Michael, Ott German, Spang Rainer, Klapper Wolfram
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group
Staiger A, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, Hansmann M, Lenze D, Ziepert M, Horn H, Scott D, Barth T, Bernd H, Feller A, Klapper W, Szczepanowski M, Hummel M, Stein H, German High-Grade Lymphoma Study Group. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol 2017; 35:2515-2526.
May 19, 2017Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group
May 19, 2017J Clin Oncol 2017; 35:2515-2526
Staiger Annette M, Hartmann Sylvia, Möller Peter, Cogliatti Sergio B., Lenz Georg, Trümper Lorenz, Löffler Markus, Schmitz Norbert, Pfreundschuh Michael, Rosenwald Andreas, Ott German, Hansmann Martin-Leo, Lenze Dido, Ziepert Marita, Horn Heike, Scott David W, Barth Thomas F E, Bernd Heinz-Wolfram, Feller Alfred C, Klapper Wolfram, Szczepanowski Monika, Hummel Michael, Stein Harald, German High-Grade Lymphoma Study Group
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
Horn H, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G, Möller P, Schmelter C, Hansmann M, Ziepert M, Becher C, Barth T, Bernd H, Feller A, Klapper W, Hummel M, Stein H, German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121:2253-63.
Jan 18, 2013MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
Jan 18, 2013Blood 2013; 121:2253-63
Horn Heike, Cogliatti Sergio B., Pfreundschuh Michael, Schmitz Norbert, Trümper Lorenz, Siebert Reiner, Loeffler Markus, Rosenwald Andreas, Ott German, Möller Peter, Schmelter Christopher, Hansmann Martin-Leo, Ziepert Marita, Becher Claudia, Barth Thomas F E, Bernd Heinz-Wolfram, Feller Alfred C, Klapper Wolfram, Hummel Michael, Stein Harald, German High-Grade Non-Hodgkin Lymphoma Study Group
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study
Thieblemont C, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Trougouboff P, Cogliatti S, Briere J, Mounier N, Voelker H, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Gisselbrecht C. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29:4079-87.
Sep 26, 2011The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study
Sep 26, 2011J Clin Oncol 2011; 29:4079-87
Thieblemont Catherine, Boudova Ludmila, Ysebaert Loic, Soulier Jean, Chevalier Catherine, Bron Dominique, Schmitz Norbert, Gaulard Philippe, Houlgatte Remi, Trougouboff Philippe, Cogliatti Sergio B., Briere Josette, Mounier Nicolas, Voelker Hans-Ullrich, Cuccuini Wendy, Hirchaud Edouard, Rosenwald Andreas, Jack Andrew, Sundstrom Christer, Gisselbrecht Christian
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
Ott G, Frank M, Hansmann M, Barth T, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Loeffler M, Müller-Hermelink H, Stein H, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd H, Thorns C, Feller A, Lenze D, Hummel M, Rosenwald A. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116:4916-25.
Aug 24, 2010Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
Aug 24, 2010Blood 2010; 116:4916-25
Ott German, Frank Matthias, Hansmann Martin-Leo, Barth Thomas F E, Möller Peter, Cogliatti Sergio B., Pfreundschuh Michael, Schmitz Norbert, Trümper Lorenz, Loeffler Markus, Müller-Hermelink Hans-Konrad, Stein Harald, Ziepert Marita, Klapper Wolfram, Horn Heike, Szczepanowski Monika, Bernd Heinz-Wolfram, Thorns Christoph, Feller Alfred C, Lenze Dido, Hummel Michael, Rosenwald Andreas
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials
Bernd H, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Höller S, Löffler M, Feller A, Barth T, Müller-Hermelink H, Rosenwald A, Ziepert M, Thorns C, Klapper W, Wacker H, Hummel M, Stein H, Hansmann M, Ott G, German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. Haematologica 2009; 94:1569-80.
Nov 1, 2009Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials
Nov 1, 2009Haematologica 2009; 94:1569-80
Bernd Heinz-Wolfram, Möller Peter, Cogliatti Sergio B., Pfreundschuh Michael, Schmitz Norbert, Trümper Lorenz, Höller Silvia, Löffler Markus, Feller Alfred C, Barth Thomas F E, Müller-Hermelink Hans-Konrad, Rosenwald Andreas, Ziepert Marita, Thorns Christoph, Klapper Wolfram, Wacker Hans-Heinrich, Hummel Michael, Stein Harald, Hansmann Martin-Leo, Ott German, German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)